Saharsh Davuluri

This episode of PharmTech Explained discusses how China's biotech surge is reshaping US drug licensing, manufacturing control, and FDA data trust, the key shifts pharma professionals must track.

Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.

Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.

Pharma manufacturing and development experts reassess their 2026 predictions for the industry and look ahead to the second half of the year.

Six months in, pharma manufacturing and development experts reassess their 2026 outlooks and predict what comes next.

Neuland's Saharsh Davuluri checks in on Chinese out-licensing, peptide capacity, and CDMO agility six months after his December 2025 predictions.

Neuland's Saharsh Davuluri revisits his December predictions for 2026, reporting steady progress on India manufacturing and AI adoption at midyear.